ImmunityBio, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities in USD from Q1 2018 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
ImmunityBio, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2018 to Q1 2024.
  • ImmunityBio, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $10.2M, a 86.7% decline year-over-year.
  • ImmunityBio, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $558M, a 139% increase from 2022.
  • ImmunityBio, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $234M, a 53.8% decline from 2021.
  • ImmunityBio, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $505M, a 235% increase from 2020.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $10.2M -$66.7M -86.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q1 2023 $76.9M +$77.2M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q1 2022 -$298K -$38.8M -101% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q1 2021 $38.5M +$38.6M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q1 2020 -$123K -$39.3M -100% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q1 2019 $39.2M +$39.3M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q1 2018 -$85K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.